Results 21 to 30 of about 79,837 (298)
Molecules, 2023 Immunogenicity is a major issue associated with the PK, efficacy, and safety evaluation of therapeutic protein products during pre-clinical and clinical studies. A multi-tiered approach consisting of screening, confirmatory, and titration assays has been
Tingting Liu +12 more
doaj +1 more source
HER2-targeting Peptide Drug Conjugate with Better Penetrability for Effective Breast Cancer Therapy
BIO Integration, 2023 Antibody-drug conjugates (ADCs) have the following advantages: target specificity; wide therapeutic index; and prolonged circulation half-life. A key limitation of ADCs, however, is the large size (~150 kDa), which markedly slows diffusion through the ...
Yixia Liang +9 more
doaj +1 more source
Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin
Clinical Medicine Insights: Oncology, 2012 Hodgkins lymphoma (HL) which has relapsed post or is refractory to autologous bone marrow transplant presents an ongoing treatment challenge. Development of monoclonal antibodies (mAb) for the treatment of HL has aimed to replicate the success of mAb ...
Michelle Furtado, Simon Rule
doaj +1 more source
Novel method for screening functional antibody with comprehensive analysis of its immunoliposome
Scientific Reports, 2021 Development of monoclonal antibody is critical for targeted drug delivery because its characteristics determine improved therapeutic efficacy and reduced side-effect.
Shusei Hamamichi +4 more
doaj +1 more source
Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based Conjugation Approaches
Pharmaceuticals, 2021 In the last few decades, antibody-based diagnostic and therapeutic applications have been well established in medicine and have revolutionized cancer managements by improving tumor detection and treatment.
Ahmad Fawzi Hussain +8 more
doaj +1 more source
Introduction to Antibody-Drug Conjugates [PDF]
Antibodies, 2021 Antibody-drug conjugates (ADCs) are innovative biopharmaceutical products in which a monoclonal antibody is linked to a small molecule drug with a stable linker. Most of the ADCs developed so far are for treating cancer, but there is enormous potential for using ADCs to treat other diseases.
openaire +3 more sources
An Immunosuppressive Antibody–Drug Conjugate [PDF]
Journal of the American Chemical Society, 2015 We have developed a novel antibody-drug conjugate (ADC) that can selectively deliver the Lck inhibitor dasatinib to human T lymphocytes. This ADC is based on a humanized antibody that selectively binds with high affinity to CXCR4, an antigen that is selectively expressed on hematopoietic cells.
Wang, Rongsheng E +13 more
openaire +4 more sources
Antibody–Drug Conjugates for Cancer Therapy [PDF]
Molecules, 2020 Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows ...
Umbreen Hafeez +3 more
openaire +4 more sources
Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
Indian Journal of Medical and Paediatric Oncology, 2019 Docetaxel, trastuzumab, and pertuzumab, known as THP, is the preferred first-line treatment for HER2-positive advanced breast cancer, and the second-line drug of choice is trastuzumab emtansine.
Manikandan Dhanushkodi
doaj +1 more source
Non-internalising antibody–drug conjugates
Chemical Society Reviews, 2022 This review introduces non-internalising Antibody–Drug Conjugates (ADCs), highlighting the linker chemistry that enables extracellular payload release.
Nicola Ashman +2 more
openaire +2 more sources